Abstract:BACKGROUND:Much evidence has demonstrated that interleukin (IL)-33 plays an important role in rheumatoid arthritis (RA). However, there have been limited studies about soluble ST2, a receptor for IL-33, in RA. The aims of this study were to detect the levels of ST2 in the serum and synovial fluid of RA patients and to reveal the association of these levels with disease activity and the function of ST2 in RA. METHODS:A total of 56 RA patients and 38 age-matched healthy controls were enrolled in this study. Synovial fluid samples were collected from another 30 RA patients and 20 osteoarthritis patients. Serum and synovial fluid levels of ST2 were measured by ELISA. In addition, the levels of ST2 in the serum of RA patients before and after therapy were detected. The function of ST2 in RA was revealed by the results of an in vitro cell assay, where recombinant ST2 proteins were used to treat peripheral blood mononuclear cells (PBMCs) and RA synovial fibroblasts (RASFs). RESULTS:Serum-soluble ST2 levels were significantly higher in RA patients (127.14 ± 61.43 pg/ml) than those in healthy controls (78.37 ± 41.93 pg/ml, P < 0.01). Synovial fluid-soluble ST2 levels (41.90 ± 33.58 pg/ml) were much higher in RA patients than those in osteoarthritis patients (19.71 ± 16.72 pg/ml, P < 0.05). RA patients who received effective therapy for 6 months showed decreased serum-soluble ST2 levels (113.01 ± 53.90 pg/ml) compared to baseline (139.59 ± 68.36 pg/ml) (P = 0.01). RA patients with high disease activity had higher serum-soluble ST2 levels (162.02 ± 56.78 pg/ml) than those with low disease activity (94.67 ± 40.27 pg/ml, P = 0.001). Soluble ST2 did not affect IL-1β, IL-6, IL-8, or tumor necrosis factor-α (TNF-α) expression in PBMCs from RA patients. However, soluble ST2 ameliorated the expressions of IL-33 and IL-1β but not that of IL-6, IL-8, or TNF-α in resting RASFs. Interestingly, in the RASFs stimulated by TNF-α plus IL-1β, soluble ST2 showed extensive suppressive effects on the expression of IL-6, IL-8, and TNF-α. CONCLUSION:Elevated levels of ST2 in the serum and synovial fluid were associated with disease activity and ameliorated IL-33 expression and IL-33-induced inflammation in RASFs, suggesting that soluble ST2 might be a potential therapeutic candidate for RA.

ST2 suppresses IL-6 production via the inhibition of IκB degradation induced by the LPS signal in THP-1 cells

Shp-2 Phosphatase Negatively Regulates The Trif Adaptor Protein-Dependent Type I Interferon And Proinflammatory Cytokine Production

Disruption of transient receptor potential melastatin 2 attenuate lipopolysaccharide-induced heme oxygenase-1 expression in mouse macrophages through p38 mitogen-activated protein kinase

Disruption of Transient Receptor Potential Melastatin 2 Attenuate Lipopolysaccharide-Induced Heme Oxygenase-1 Expression in Mouse Macrophages Through P38 Mitogen-Activated Protein Kinase (P5202)

Endogenous Interleukin-6 Plays A Crucial Protective Role In Streptococcal Toxic Shock Syndrome Via Suppression Of Tumor Necrosis Factor Alpha Production

STAP-2 negatively regulates BCR-mediated B cell activation by recruiting tyrosine-protein kinase CSK to LYN

Synovial regulatory T cells expressing ST2 deteriorate joint inflammation through the suppression of immunoregulatory eosinophils

The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response.

The Essential Role Of Single Ig Il-1 Molecule/Toll Il-1r8 In Regulation Immune Response

IL-37 isoform D acts as an inhibitor of soluble ST2 to boost type 2 immune homeostasis in white adipose tissue

Selective Sequestration of STAT1 in the Cytoplasm Via Phosphorylated SHP-2 Ameliorates Murine Experimental Colitis

Suppression of IL-12 Production by Tristetraprolin through Blocking NF-кB Nuclear Translocation

Elevated Levels of Soluble ST2 were Associated with Rheumatoid Arthritis Disease Activity and Ameliorated Inflammation in Synovial Fibroblasts.

Il-33, an Interleukin-1-Like Cytokine That Signals Via the Il-1 Receptor-Related Protein St2 and Induces T Helper Type 2-Associated Cytokines

Conformational Sampling and Binding Site Assessment of Suppression of Tumorigenicity 2 Ectodomain.

[SIRT1 Inhibits IL-1β Mrna Transcription in Lipopolysaccharide Tolerant THP-1 Cells].

TSLP is a negative regulator of RANKL-induced osteoclastogenesis

Dipyrithione Inhibits Ifn-Gamma-Induced Jak/Stat1 Signaling Pathway Activation And Ip-10/Cxcl10 Expression In Raw264.7 Cells

Macrophage Inflammatory Protein-2 in High Mobility Group Box 1 Secretion of Macrophage Cells Exposed to Lipopolysaccharide.

ILC2s Improve Glucose Metabolism Through the Control of Saturated Fatty Acid Absorption Within Visceral Fat

Suppressive effect of tanshinone ⅡA on HMGB1 release from lipopolysaccharide-induced macrophages